Why the study?
Does quinapril provide greater cardioprotection than enalapril in a rat model of heart failure?
Does quinapril provide greater cardioprotection than enalapril in a rat model of heart failure?
In a rat model of heart failure, high-dose quinapril provided greater reduction in left ventricular end-diastolic pressure and TGF-beta1 mRNA expression compared to enalapril.
High-dose quinapril effects in rat HF are hypothesis-generating; clinical translation and superiority remain untested.
The cardioprotective properties of angiotensin-converting enzyme (ACE) inhibitors, quinapril and enalapril were studied in a rat model of heart failure. Seventy-five rats were divided into five groups and administered quinapril or enalapril at 2 and 20 mg/kg/day (groups Q2, Q20, E2 and E20) or vehicle alone (group V, all groups n = 15). Although both ACE inhibitors improved survival rate and ventricular function in a dose-dependent manner, the left ventricular end-diastolic pressure and expression level of transforming growth factor-beta1 mRNA were the lowest in group Q20. These results suggest that quinapril may confer greater protection than enalapril against injury from the renin-angiotensin system in heart failure.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: